Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone-Reference-Cited by-同舟云学术

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Published:2019-10 Issue:4 Volume:76 Page:418-424
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Efstathiou Eleni,Davis John W.,Pisters Louis,Li Weimin,Wen Sijin,McMullin Ryan P.,Gormley Michael,Ricci Deborah,Titus Mark,Hoang Anh,Zurita Amado J.,Tran NamPhuong,Peng Weimin,Kheoh Thian,Molina Arturo,Troncoso Patricia,Logothetis Christopher J.

Funder

Prostate Cancer Foundation

Janssen Research & Development

Publisher

Elsevier BV

Subject

Urology

Reference11 articles.

1. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

2. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

3. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study;Taplin;J Clin Oncol,2014

4. The genomic complexity of primary human prostate cancer;Berger;Nature,2011

5. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade;Arora;Cell,2013

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy;International Journal of Urology;2024-09-10

2. Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches;Cancers;2024-07-05

3. A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates;BJU International;2024-06-04

4. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis;Clinical Genitourinary Cancer;2024-06

5. The role of androgen deprivation therapy prior to radical prostatectomy in high-risk prostate cancer: a systematic review;Minerva Urology and Nephrology;2024-05